In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.
J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.
Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...
Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
Congestive Heart Failure Treatment Market Predicted Growth At 4.47% CAGR To 35.5 Billion USD By 2032 Gilead Sciences The Global Congestive Heart Failure Treatment market is witnessing significant ...
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...
Having peers facilitate virtual visits may lead to many more patients with hepatitis C receiving treatment and clearing the ...
Almost 1 in 10 patients receiving HIV care may have binge eating disorder (BED), a significantly higher rate than the 0.3% ...